u/Pete26l96

Reddit r/ValueInvesting
· отслеживается с фев 2026
Сигналы
4
Винрейт
75.0%
доходность
+13.4%
Сигналы 4 2 Постов отслежено · 0.0/день
Сигналы
0
30д 0
90д 0
Лучшие сигналы
AMZN Лонг +23.3%
GOOGL Лонг +19.1%
NVO Лонг +18.0%
Худшие сигналы
META Лонг -6.8%
Самые упоминаемые
META ×1
AMZN ×1
NVO ×1
Последние сигналы
META Лонг 5 месяцев назад
AMZN Лонг 5 месяцев назад
GOOGL Лонг 5 месяцев назад
Винрейт 75% Лонг 4 Шорт 0
Винрейт
75%
30д 75%
90д 75%
Средняя доходность +13.4% Доходность лонгов +13.4% Доходность шортов -
Средняя доходность
+3.8%
30д +12.8%
90д +9.0%
Загрузка графиков...
Результат
Результат
Сортировка
Тема Позиция
Тикер
Сторона
Упоминания
Первый колл
Цена колла
P&L
Тезис
Тема
Источник
Лонг
26 мар
$210.50
+23.3%
AWS leads Azure in infrastructure and output. Amazon offers a more compelling infrastructure play with a wider moat than Microsoft. Amazon is a better buy than MSFT despite lagging stock performance over the last 5 years. Slowdown in cloud spending or retail margin compression.
AWS leads Azure in infrastructure and output. Amazon offers a more compelling infrastructure play with a wider moat than Microsoft. Amazon is a better buy than MSFT despite lagging stock performance over the last 5 years. Slowdown in cloud spending or retail margin compression.
Гиперскейлеры
Лонг
26 мар
$289.83
+19.1%
Google is at the forefront of AI and innovation, and Gsuite is replacing Office in government sectors. For a slightly higher valuation than MSFT, Google offers superior technological leadership and market share capture. Buy Google over MSFT for better long-term value and AI exposure. Regulatory/antitrust risks or failure to monetize AI effectively.
Google is at the forefront of AI and innovation, and Gsuite is replacing Office in government sectors. For a slightly higher valuation than MSFT, Google offers superior technological leadership and market share capture. Buy Google over MSFT for better long-term value and AI exposure. Regulatory/antitrust risks or failure to monetize AI effectively.
Гиперскейлеры
Лонг
26 мар
$593.00
-6.8%
Meta has a very tight grip on the social media landscape. Meta's monopoly in social media is stronger than Microsoft's current grip on the software/hardware space. Meta makes more sense as a long-term investment than MSFT. Ad-spending downturns or regulatory actions against social media.
Meta has a very tight grip on the social media landscape. Meta's monopoly in social media is stronger than Microsoft's current grip on the software/hardware space. Meta makes more sense as a long-term investment than MSFT. Ad-spending downturns or regulatory actions against social media.
Гиперскейлеры
Лонг
23 фев
$39.63
+18.0%
NVO's stock price has dropped significantly due to negative news about a single drug trial, falling from a high of ~1000 DKK to ~250 DKK. The speaker argues that the market is irrationally focused on the speculative weight-loss drug pipeline while ignoring the stable, profitable core business in insulin. They assert that the company's fundamentals remain intact and the sell-off is driven by "stupid people" and sentiment, not a change in intrinsic value. This has pushed the stock from an overvalued "To the moon!" price into undervalued territory. This is a fundamental value investing opportunity. The thesis is to buy a high-quality company with a stable core business after its price has been punished by market irrationality and short-term sentiment, creating a significant margin of safety. The speaker's assessment that the weight-loss drug market is just "hype" could be wrong; this market could become the primary value driver for NVO and its competitors. A permanent loss of competitive ground to Eli Lilly in this segment could severely impair future growth and justify a lower valuation, making the current price a value trap rather than a bargain. TICKER - DIRECTION
NVO's stock price has dropped significantly due to negative news about a single drug trial, falling from a high of ~1000 DKK to ~250 DKK. The speaker argues that the market is irrationally focused on the speculative weight-loss drug pipeline while ignoring the stable, profitable core business in insulin. They assert that the company's fundamentals remain intact and the sell-off is driven by "stupid people" and sentiment, not a change in intrinsic value. This has pushed the stock from an overvalued "To the moon!" price into undervalued territory. This is a fundamental value investing opportunity. The thesis is to buy a high-quality company with a stable core business after its price has been punished by market irrationality and short-term sentiment, creating a significant margin of safety. The speaker's assessment that the weight-loss drug market is just "hype" could be wrong; this market could become the primary value driver for NVO and its competitors. A permanent loss of competitive ground to Eli Lilly in this segment could severely impair future growth and justify a lower valuation, making the current price a value trap rather than a bargain. TICKER - DIRECTION
GLP-1 / Ожирение
Показано 4 из 4 коллов · сортировка по упоминаниям

У u/Pete26l96 на Buzzberg отслеживается 4 торговых идей по 4 тикерам с февраля 2026. Чаще всего покрывает: META, AMZN, NVO.